|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/00 | |
| A61F 5/00 | |||
| A61M 5/145 | |||
| A61K 38/26 | |||
| A61M 5/142 | |||
| A61L 27/54 | |||
| A61K 38/00 |
| (11) | Number of the document | 3323423 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17186130.5 |
| Date of filing the European patent application | 2010-09-21 | |
| (97) | Date of publication of the European application | 2018-05-23 |
| (45) | Date of publication and mention of the grant of the patent | 2020-06-17 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 277724 P | 2009-09-28 | US | |
| 358112 P | 2010-06-24 | US |
| (72) |
ALESSI, Thomas R., US
LUSKEY, Kenneth L., US
|
| (73) |
Intarcia Therapeutics, Inc,
One Marina Park Drive, Suite 1300, Boston, MA 02210,
US
|
| (54) | RAPID ESTABLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STEADY-STATE DRUG DELIVERY |
| RAPID ESTABLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STEADY-STATE DRUG DELIVERY |